| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer (NCT05364645) | SWOG Cancer Research Network | 2022-07-25 |
| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (NCT05334329) | University of California, Irvine | 2022-07-20 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (NCT05098210) | Fred Hutchinson Cancer Center | 2022-06-09 |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial (NCT05339022) | Ohio State University Comprehensive Cancer Center | 2022-04-14 |
| A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer (NCT05215769) | Ohio State University Comprehensive Cancer Center | 2022-03-30 |
| Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT05096663) | SWOG Cancer Research Network | 2022-03-15 |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (NCT05166616) | City of Hope Medical Center | 2022-03-07 |
| Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer (NCT05017025) | M.D. Anderson Cancer Center | 2022-02-17 |
| Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer (NCT04919382) | Dwight Owen | 2022-01-26 |
| Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NCT04780568) | Ohio State University Comprehensive Cancer Center | 2022-01-18 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (NCT04514497) | National Cancer Institute (NCI) | 2021-10-20 |
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (NCT04919369) | Dwight Owen | 2021-10-18 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942) | National Cancer Institute (NCI) | 2021-08-25 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery (NCT04588246) | NRG Oncology | 2021-08-05 |
| Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (NCT04639245) | Fred Hutchinson Cancer Center | 2021-07-19 |
| Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer (NCT04971187) | M.D. Anderson Cancer Center | 2021-06-30 |
| Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer (NCT05045404) | M.D. Anderson Cancer Center | 2021-06-16 |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability (NCT04804644) | NRG Oncology | 2021-06-08 |
| A Biobehavioral/Cognitive Treatment for Stress, Depression, and Anxiety in Patients With Stage IV Lung Cancer (NCT05342571) | Ohio State University Comprehensive Cancer Center | 2021-06-01 |
| Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity (NCT04954885) | Ohio State University Comprehensive Cancer Center | 2021-05-18 |
| Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT04625647) | SWOG Cancer Research Network | 2021-04-16 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer (NCT04216316) | National Cancer Institute (NCI) | 2021-04-14 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040) | M.D. Anderson Cancer Center | 2021-04-14 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies (NCT04785287) | M.D. Anderson Cancer Center | 2021-03-29 |
| Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer (NCT04837716) | M.D. Anderson Cancer Center | 2021-03-18 |
| A Nurse-Led Intervention for Fear of Progression in Advanced Cancer (NCT04819997) | City of Hope Medical Center | 2021-03-08 |
| MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer (NCT04762199) | Emory University | 2021-02-24 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (NCT03819296) | M.D. Anderson Cancer Center | 2021-02-21 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study (NCT05022394) | M.D. Anderson Cancer Center | 2021-02-18 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (NCT04752267) | University of Southern California | 2021-02-15 |
| Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer (NCT04751747) | Rutgers, The State University of New Jersey | 2021-02-11 |
| BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced Lung Cancers (NCT05640765) | Mayo Clinic | 2021-02-03 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (NCT04728230) | M.D. Anderson Cancer Center | 2021-01-05 |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060) | National Cancer Institute (NCI) | 2020-12-28 |
| Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer (NCT04533451) | Alliance for Clinical Trials in Oncology | 2020-11-16 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (NCT04250545) | National Cancer Institute (NCI) | 2020-10-26 |
| Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer (NCT04396535) | Mayo Clinic | 2020-10-23 |
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT04267913) | SWOG Cancer Research Network | 2020-09-05 |
| Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis (NCT04516070) | M.D. Anderson Cancer Center | 2020-08-28 |
| Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer (NCT04946279) | OHSU Knight Cancer Institute | 2020-08-07 |
| Family Caregivers in Underserved Populations Providing Complex Cancer Care (NCT05213078) | City of Hope Medical Center | 2020-07-15 |
| Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (NCT04310007) | National Cancer Institute (NCI) | 2020-07-13 |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer (NCT04479306) | M.D. Anderson Cancer Center | 2020-06-18 |
| Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (NCT04340882) | Emory University | 2020-06-05 |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy (NCT03965689) | National Cancer Institute (NCI) | 2020-04-16 |
| Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (NCT04268550) | SWOG Cancer Research Network | 2020-04-08 |
| Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer (NCT04262869) | Emory University | 2020-03-27 |
| Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer (NCT03831932) | National Cancer Institute (NCI) | 2020-03-16 |
| Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC (NCT04227028) | City of Hope Medical Center | 2020-03-09 |
| Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) (NCT04173507) | SWOG Cancer Research Network | 2020-02-14 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Resiliency Among Older Adults Receiving Lung Cancer Treatment (NCT04229381) | Ohio State University Comprehensive Cancer Center | 2020-01-22 |
| Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer (NCT04073745) | Roswell Park Cancer Institute | 2019-12-04 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy (NCT04186988) | University of California, Davis | 2019-11-05 |
| PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer (NCT04151940) | University of Washington | 2019-09-26 |
| Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC (NCT04081688) | Rutgers, The State University of New Jersey | 2019-09-11 |
| Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study (NCT04430725) | M.D. Anderson Cancer Center | 2019-08-07 |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NCT03737994) | National Cancer Institute (NCI) | 2019-07-25 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT03546361) | Jonsson Comprehensive Cancer Center | 2019-07-08 |
| Insomnia in Patients With Metastatic Lung Cancer (NCT06472804) | Mayo Clinic | 2019-06-19 |
| Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer (NCT03995667) | OHSU Knight Cancer Institute | 2019-06-11 |
| Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) (NCT03971474) | SWOG Cancer Research Network | 2019-05-28 |
| Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT03845296) | SWOG Cancer Research Network | 2019-04-16 |
| Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (NCT03793179) | National Cancer Institute (NCI) | 2019-04-05 |
| Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer (NCT03581487) | M.D. Anderson Cancer Center | 2019-04-01 |
| Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers (NCT03902535) | City of Hope Medical Center | 2019-03-08 |
| Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (NCT03830918) | Jonsson Comprehensive Cancer Center | 2019-03-06 |
| Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer (NCT03944265) | Thomas Jefferson University | 2019-02-08 |
| Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers (NCT03948100) | M.D. Anderson Cancer Center | 2018-12-20 |
| Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (NCT03707938) | M.D. Anderson Cancer Center | 2018-12-18 |
| Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers (NCT04662645) | Ohio State University Comprehensive Cancer Center | 2018-12-12 |
| Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer (NCT03600701) | National Cancer Institute (NCI) | 2018-11-29 |
| Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer (NCT03637816) | M.D. Anderson Cancer Center | 2018-11-27 |
| Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment (NCT03731585) | M.D. Anderson Cancer Center | 2018-11-15 |
| Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer (NCT03776253) | City of Hope Medical Center | 2018-11-15 |
| Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer (NCT03662074) | Wake Forest University Health Sciences | 2018-11-07 |
| Bronchoscopic Laser Ablation of Peripheral Lung Tumors (NCT03707925) | M.D. Anderson Cancer Center | 2018-09-18 |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (NCT03590054) | Rahul Aggarwal | 2018-08-20 |
| Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery (NCT03582124) | Stanford University | 2018-07-19 |
| Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (NCT02971501) | National Cancer Institute (NCI) | 2018-06-27 |
| Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease (NCT03025256) | M.D. Anderson Cancer Center | 2018-05-02 |
| Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced (NCT03225664) | M.D. Anderson Cancer Center | 2018-02-03 |
| Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study (NCT03410043) | M.D. Anderson Cancer Center | 2018-01-17 |
| Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer (NCT03391869) | M.D. Anderson Cancer Center | 2017-12-29 |
| Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors (NCT02589522) | National Cancer Institute (NCI) | 2017-05-22 |
| CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (NCT02955290) | Roswell Park Cancer Institute | 2016-12-22 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02595931) | National Cancer Institute (NCI) | 2016-07-22 |
| Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663) | National Cancer Institute (NCI) | 2016-05-11 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866) | National Cancer Institute (NCI) | 2016-04-04 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types (NCT06075524) | Mayo Clinic | 2015-06-15 |
| 4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis (NCT00862680) | M.D. Anderson Cancer Center | 2009-03-12 |